2,5-二氟-3-硝基甲苯 | 1093758-82-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,5-二氟-3-硝基甲苯
• 英文名称: 2,5-Difluoro-1-methyl-3-nitrobenzene
• CAS: 1093758-82-7
• 化学式: C7H5F2NO2
• mdl: MFCD11519028
• 分子量: 173.12
• InChiKey: JPBHCSGGXITIHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2904909090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P261,P280,P305+P351+P338,P311
• 危险品运输编号：
  2811
• 危险性描述：
  H302,H312,H315,H319,H331,H335

反应信息

• 作为反应物：
  描述：

  2,5-二氟-3-硝基甲苯 在 5%-palladium/activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 生成 2,5-Difluoro-3-methylaniline
  参考文献：
  名称：

  NOVEL ALPK1 INHIBITORS

  摘要：

  The disclosure is directed to novel ALPK1 inhibitors having the Formula (I), or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, a stable isotopic variant, a prodrug, or a crystal form thereof. The disclosure is also directed to pharmaceutical composition comprising the novel ALPK1 inhibitors, and use thereof in treating inflammation related diseases, such as ROSAH syndrome, inflammatory bowel disease (IBD), NASH, gout, diabetes, chronic kidney disease, pancreatitis, Kawasaki disease, inflammatory skin diseases and neurodegenerative diseases including the Alzheimer's disease.

  公开号：

  WO2024153225A1
• 作为产物：
  描述：

  2,5-二氟甲苯 、 potassium nitrate 、 在 乙酸乙酯 、 Sodium sulfate-III 作用下， 以 硫酸 为溶剂， 反应 16.0h， 以to afford 0.555 g (91%) of the title compound as a light red oil的产率得到2,5-二氟-3-硝基甲苯
  参考文献：
  名称：

  Alkyl, azido, alkoxy and fluoro-substituted and fused quinoxalinediones

  摘要：

  本发明揭示了通过向需要此类治疗的动物投与具有高结合甘氨酸受体的烷基或偶氮基取代的1,4-二氢喹啉-2,3-二酮或其药学上可接受的盐，来治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元丢失，以及治疗包括阿尔茨海默病、肌萎缩性侧索硬化症、亨廷顿病和唐氏综合征在内的神经退行性疾病，治疗兴奋性氨基酸过度活跃的不良后果，以及治疗焦虑、慢性疼痛、惊厥和诱导麻醉的方法。

  公开号：

  US06147075A1

文献信息

• US6147075A
  申请人：——

  公开号：US6147075A

  公开（公告）日：2000-11-14
• Alkyl, azido, alkoxy and fluoro-substituted and fused quinoxalinediones
  申请人：CoCensys, Inc.

  公开号：US06147075A1

  公开（公告）日：2000-11-14

  Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, and inducing anesthesia are disclosed by administering to an animal in need of such treatment an alkyl or azido-substituted 1,4-dihydroquinoxaline-2,3-dione or pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.

  本发明揭示了通过向需要此类治疗的动物投与具有高结合甘氨酸受体的烷基或偶氮基取代的1,4-二氢喹啉-2,3-二酮或其药学上可接受的盐，来治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元丢失，以及治疗包括阿尔茨海默病、肌萎缩性侧索硬化症、亨廷顿病和唐氏综合征在内的神经退行性疾病，治疗兴奋性氨基酸过度活跃的不良后果，以及治疗焦虑、慢性疼痛、惊厥和诱导麻醉的方法。
• NOVEL ALPK1 INHIBITORS
  申请人：[en]PYROTECH (BEIJING) BIOTECHNOLOGY CO., LTD.

  公开号：WO2024153225A1

  公开（公告）日：2024-07-25

  The disclosure is directed to novel ALPK1 inhibitors having the Formula (I), or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, a stable isotopic variant, a prodrug, or a crystal form thereof. The disclosure is also directed to pharmaceutical composition comprising the novel ALPK1 inhibitors, and use thereof in treating inflammation related diseases, such as ROSAH syndrome, inflammatory bowel disease (IBD), NASH, gout, diabetes, chronic kidney disease, pancreatitis, Kawasaki disease, inflammatory skin diseases and neurodegenerative diseases including the Alzheimer's disease.